Co-Occurring LKB1 Deficiency Determinates the Susceptibility to ERK-Targeted Therapy in RAS-Mutant Lung Cancer

J Thorac Oncol. 2020 Apr;15(4):e58-59. doi: 10.1016/j.jtho.2020.01.004.

Author

Affiliation

¹ Department of General Thoracic Surgery, Department of BioMedical Research, Inselspital, Bern University Hospital, University of Bern, Switzerland, Murtenstrasse, Bern, Switzerland. Electronic address: haitang.yang@dbmr.unibe.ch.

PMID: 32216949
DOI: 10.1016/j.jtho.2020.01.004

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung*
Humans
Lung Neoplasms*
Protein Serine-Threonine Kinases

Substances

Protein Serine-Threonine Kinases